Nasus Pharma Ltd.

What Nasus Pharma Ltd. does

Nausus Pharma Ltd. is a clinical-stage pharmaceutical company, headquartered in Tel Aviv, Israel, and listed on NYSE American under ticker NSRX. Founded in 2019, the company is developing a portfolio of powder-based intranasal drug products for acute, life-threatening medical emergencies. Its proprietary Nasax® platform uses uniform-sized spherical active pharmaceutical ingredients combined with an inhalation-approved carrier to enable rapid, precise intranasal delivery of drugs to the bloodstream and brain, with stability data suggesting longer shelf life compared to liquid formulations.

The company's lead asset is NS002, an intranasal epinephrine powder candidate for anaphylaxis. Phase 2 data showed a median time to therapeutic threshold of 1.69 minutes versus 3.42 minutes for EpiPen (p=0.033), with 88.4% of NS002 participants reaching the 100 pg/mL threshold at 5 minutes versus 64.6% for EpiPen, and a 47% higher early-exposure AUC. The second asset, NS001, is an intranasal naloxone powder for opioid overdose reversal that completed a pivotal Phase 3 study (n=42) demonstrating faster delivery and higher absorption than Narcan®, and is explicitly described as available for partnering. Three earlier-stage programs — NS003 (intranasal ondansetron for chemotherapy-induced nausea), NS004 (undisclosed molecule for metabolic disorders), and NS005 (cardiovascular) — are in preclinical development with first-in-human studies planned for H2 2026.

Nasus Pharma is pre-commercial and generates no revenue. The business model relies on future pharmaceutical product sales following regulatory approvals (self-commercialization planned for NS002 with an NDA filing targeted after pivotal trials) and partnering/out-licensing for NS001. The company raised $15 million in a February 2026 private placement, held $4.3 million in cash and marketable securities as of December 31, 2025, and reported a $5.9 million net loss for the year ended December 31, 2025. Management is led by CEO Dan Teleman (joined January 2025) and CFO Eyal Rubin (appointed November 2025), with co-founder Dr. Dalia Megiddo serving as Chief Development Officer. Customer engagement is directed at the medical/scientific community and institutional investors through KOL events, medical conference presentations, and investor forums, rather than direct-to-consumer channels.

Name

Nasus Pharma Ltd.

Legal name

Nasus Pharma Ltd.

Website

https://nasuspharma.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Nasus Pharma Ltd. is a clinical-stage Israeli pharmaceutical company (NYSE American: NSRX) developing powder-based intranasal drug products — lead candidate NS002 (epinephrine for anaphylaxis) and NS001 (naloxone for opioid overdose) — using its proprietary Nasax® intranasal powder delivery platform.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Intranasal drug delivery
• Anaphylaxis treatment
• Opioid overdose reversal
• Pharmaceutical drug development
• Powder formulation technology

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales (Future): Pre-commercial clinical-stage company with no current revenue. The company is developing intranasal powder products for acute medical conditions (anaphylaxis, opioid overdose). Future revenue expected from product sales following regulatory approvals and commercialization.
2. Partnering/Licensing (NS001): NS001 naloxone product is described as 'available for partnering', suggesting the company may pursue out-licensing agreements for this asset rather than self-commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Nasus Pharma is a clinical-stage pharmaceutical company developing powder-based intranasal (PBI) drug candidates for acute, life-threatening medical emergencies. Its proprietary Nasax® platform underpins lead programs NS002 (intranasal epinephrine for anaphylaxis) and NS001 (intranasal naloxone for opioid overdose), with earlier pipeline assets NS003, NS004, and NS005 in preclinical development. The company is advancing its products through clinical trials toward regulatory approval and commercialization.

Product overview

Nasus Pharma Ltd. is a clinical-stage pharmaceutical company developing a portfolio of powder-based intranasal therapies for acute, life-threatening medical emergencies. The company's proprietary Nasax Platform underlies its pipeline of drug candidates: NS002 (epinephrine for anaphylaxis) and NS001 (naloxone for opioid overdose) represent the lead programs, while NS003 (ondansetron for chemotherapy-induced nausea), NS004 (metabolic disorders), and NS005 (cardiovascular) are earlier-stage candidates. The company is headquartered in Tel Aviv, Israel, and is listed on NYSE American (NSRX).

Differentiator

Problem solved

Functional benefit

Brands

• Nasax® Platform: Proprietary powder formulation technology for intranasal drug delivery, enabling rapid and precise delivery of drugs to bloodstream and brain with potential for longer shelf-life compared to liquid formulations.
• Taffix Nasal Spray

Products and services

• NS002 (Intranasal Epinephrine Powder) Intranasal epinephrine powder drug candidate for the emergency treatment of anaphylaxis. Phase 2 data showed faster and higher absorption than EpiPen, with median time to therapeutic threshold of 1.69 minutes versus 3.42 minutes for EpiPen. The product is needle-free and being developed for patients at risk of severe allergic reactions including those with food, insect sting, and drug allergies.
• NS001 (Intranasal Naloxone Powder) Intranasal powder formulation of naloxone designed for rapid emergency reversal of opioid overdose. Completed pivotal Phase 3 study (n=42) demonstrating faster absorption and higher systemic levels compared to Narcan. The product is available for partnering and is targeted at first responders, harm-reduction programs, and individuals at risk of opioid overdose.
• NS003 (Intranasal Ondansetron Powder) Ondansetron intranasal powder candidate for the treatment of chemotherapy-induced nausea and vomiting. Preclinical stage with first-in-human study planned for H2 2026.
• NS004 (Metabolic Disorder Candidate) Undisclosed molecule intranasal powder candidate for metabolic disorders. Preclinical stage with first-in-human study planned for H2 2026.
• NS005 (Cardiovascular Candidate) Cardiovascular drug candidate in preclinical stage, with development details to be determined.
• Taffix Nasal Spray Nasal spray product manufactured by Nasus Pharma.

Quantifiable outcome

• NS002 achieved median time to therapeutic threshold (T100) of 1.69 minutes vs 3.42 minutes for EpiPen (p=0.033)
• +5 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Strategic Partners for NS001minorStrategic or Co-development PartnerNS001 naloxone product is described as 'available for partnering', indicating the company is seeking partners for commercialization of this asset. No specific partners named in the source material.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ARS Pharmaceuticals: Develops and now markets neffy, the first FDA-approved intranasal epinephrine spray for anaphylaxis — the most direct competitor to Nasus's NS002, targeting the same patient population with a needle-free nasal delivery format.
• Amphastar Pharmaceuticals: Manufactures and markets naloxone injection products and intranasal naloxone — a direct comparator to Nasus's NS001 for opioid overdose reversal, with established U.S. distribution.
• Emergent BioSolutions: Markets Narcan®, the leading intranasal naloxone for opioid overdose reversal, and competes directly with Nasus's NS001 powder formulation in the same indication and emergency-response channel.

Broad incumbents

• Viatris: Markets EpiPen, the dominant epinephrine auto-injector and Nasus's primary competitor for NS002. Also distributes branded and generic emergency-care products through established payor and pharmacy channels.
• Pfizer: Large pharmaceutical company with an emergency-medicine portfolio including competing epinephrine injectors and broader anaphylaxis and opioid-overdose therapeutics relevant to Nasus's indications.
• Hikma Pharmaceuticals: Markets injectable epinephrine and generic emergency medicines including naloxone, competing in the same therapeutic indications as Nasus's NS002 and NS001 with established injectable and nasal alternatives.
• Teva Pharmaceutical Industries: Sells generic epinephrine auto-injectors and other emergency-care products in the U.S., directly overlapping Nasus's NS002 indication with lower-priced incumbent alternatives.

Emerging players

• Adamis Pharmaceuticals: Developed Symjepi, a compact pre-filled epinephrine syringe, as an alternative to EpiPen — comparable to Nasus as a smaller competitor seeking to disrupt the epinephrine auto-injector market.
• Bryn Pharma: Privately-held clinical-stage company developing an intranasal epinephrine spray (Utuly®) for anaphylaxis — directly comparable to NS002 as a needle-free epinephrine alternative to EpiPen.
• Indivior: Focused on opioid use disorder and overdose treatment, including naloxone products — overlaps with Nasus's NS001 indication and shares the emergency-response commercial channel.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nasus Pharma Ltd.